P.C.M. van de Kerkhof

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

Kim Papp, Stephen K. Tyring, M. Lahfa et al. · British Journal of Dermatology · 2005 · 692 citations

Medicine, Dermatology, Pharmacotherapy +8

Psoriasis is associated with increased β-defensin genomic copy number

Edward J. Hollox, Ulrike Hüffmeier, Patrick L.J.M. Zeeuwen et al. · Nature Genetics · 2007 · 621 citations · Full text

Medicine, Genetics, Molecular Genetics +12

Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

Mark Lebwohl, H. Bachelez, Giampiero Girolomoni et al. · Journal of the American Academy of Dermatology · 2014 · 511 citations

Medicine, Dermatology, Health Sciences +6

European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>

Alexander Nast, Paolo Gisondi, Anthony D. Ormerod et al. · Journal of the European Academy of Dermatology and Venereology · 2015 · 395 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

H. Bachelez, P.C.M. van de Kerkhof, Robert Strohal et al. · The Lancet · 2015 · 394 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8